<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002881" GROUP_ID="AIRWAYS" ID="520100091910032809" MERGED_FROM="" MODIFIED="2017-08-21 16:47:20 +0100" MODIFIED_BY="Emma Dennett" NOTES="&lt;p&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.1&lt;/p&gt;&lt;p&gt;Liz Arnold read and approved search strategy - 131004&lt;/p&gt;" NOTES_MODIFIED="2017-08-21 16:42:49 +0100" NOTES_MODIFIED_BY="Emma J Dennett" REVIEW_NO="CAR-COP" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2017-08-21 16:41:33 +0100" MODIFIED_BY="Emma J Dennett">
<TITLE>Carbonic anhydrase inhibitors for hypercapnic ventilatory failure in chronic obstructive pulmonary disease</TITLE>
<CONTACT>
<PERSON ID="7702" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Paul</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Jones</LAST_NAME>
<SUFFIX/>
<POSITION>Professor</POSITION>
<EMAIL_1>pjones@sgul.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cardiovascular Medicine</DEPARTMENT>
<ORGANISATION>St George's Hospital Medical School</ORGANISATION>
<ADDRESS_1>Cranmer Terrace</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>SW17 0RE</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 20 8725 5371</PHONE_1>
<PHONE_2/>
<FAX_1>+44 20 8725 5955</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2017-08-21 16:39:32 +0100" MODIFIED_BY="Emma Dennett">
<PERSON ID="7702" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Paul</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Jones</LAST_NAME>
<SUFFIX/>
<POSITION>Professor</POSITION>
<EMAIL_1>pjones@sgul.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cardiovascular Medicine</DEPARTMENT>
<ORGANISATION>St George's Hospital Medical School</ORGANISATION>
<ADDRESS_1>Cranmer Terrace</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>SW17 0RE</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 20 8725 5371</PHONE_1>
<PHONE_2/>
<FAX_1>+44 20 8725 5955</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7552" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Michael</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Greenstone</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant Chest Physician</POSITION>
<EMAIL_1>mike.greenstone@hey.nhs.uk</EMAIL_1>
<EMAIL_2>greenstone.mike@googlemail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Castle Hill Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Cottingham</CITY>
<ZIP>HU16 5JQ</ZIP>
<REGION>North Humberside</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1482 875875</PHONE_1>
<PHONE_2/>
<FAX_1>+44 1482 876331</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2010-10-28 15:55:18 +0100" MODIFIED_BY="Emma J Welsh" NOTES="&lt;p&gt;New studies sought but none found: 05/10/07&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 07/10/03&lt;/p&gt;" NOTES_MODIFIED="2010-10-28 15:55:18 +0100" NOTES_MODIFIED_BY="Emma J Welsh">
<UP_TO_DATE>
<DATE DAY="27" MONTH="10" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="27" MONTH="10" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="26" MONTH="10" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2001"/>
</DATES>
<WHATS_NEW MODIFIED="2017-08-21 16:41:33 +0100" MODIFIED_BY="Emma J Dennett" NOTES="&lt;p&gt;Search update run in October 2007: no new references found. &lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2017-08-21 16:41:33 +0100" NOTES_MODIFIED_BY="Emma J Dennett">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-08-21 16:41:33 +0100" MODIFIED_BY="Emma J Dennett">
<DATE DAY="21" MONTH="8" YEAR="2017"/>
<DESCRIPTION>
<P>New literature search run to assess the need to update this review. Three potentially eligible studies identified and added to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-08-21 16:40:09 +0100" MODIFIED_BY="Emma J Dennett">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-08-21 16:40:09 +0100" MODIFIED_BY="Emma J Dennett">
<DATE DAY="28" MONTH="10" YEAR="2010"/>
<DESCRIPTION>
<P>New literature search run. No new studies found. Minor copy edits made.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-10-28 15:55:28 +0100" MODIFIED_BY="Emma J Welsh">
<DATE DAY="21" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="19" MONTH="9" YEAR="2000"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>NHS Research and Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-10-28 16:25:17 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-07-21 16:23:25 +0100" MODIFIED_BY="Toby J Lasserson">
<TITLE MODIFIED="2008-07-21 16:23:25 +0100" MODIFIED_BY="Toby J Lasserson">Carbonic anhydrase inhibitors for hypercapnic ventilatory failure in chronic obstructive pulmonary disease</TITLE>
<SUMMARY_BODY>
<P>Some people with advanced chronic lung disease (COPD - chronic bronchitis or emphysema) can experience breathing failure. This involves chemical changes which in turn can lower the drive to breathe. The drug acetazolamide is used for mountain sickness, and it can stimulate breathing in some circumstances. The review of trials found that a few days of using acetazolamide can improve the level of oxygen in the blood of people with COPD. It is not clear if this leads to better outcomes, so more research is needed. Not enough data were reported on the safety of the drug. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-10-28 16:03:29 +0100" MODIFIED_BY="Emma J Welsh">
<ABS_BACKGROUND>
<P>Carbonic anhydrase inhibitors such as acetazolamide cause a mild metabolic acidosis and may stimulate breathing. Some patients with severe chronic obstructive pulmonary disease (COPD) develop chronic hypercapnic ventilatory failure. In theory, they may benefit from use of these drugs with a fall in arterial carbon dioxide level (PCO2) and a rise in arterial oxygen (PO2).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-10-28 16:03:29 +0100" MODIFIED_BY="Emma J Welsh">
<P>To determine the effectiveness and safety of acetazolamide in the treatment of hypercapnic ventilatory failure due to COPD.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-10-28 15:56:16 +0100" MODIFIED_BY="Emma J Welsh">
<P>The Cochrane Airways Group Specialised Register was searched with predefined search terms. Searches were current as of October 2010.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Trials were included in the review provided they were placebo controlled, carried out in patients with stable chronic ventilatory failure due to COPD. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-10-28 16:01:23 +0100" MODIFIED_BY="Emma J Welsh">
<P>Data were extracted and analysed by two reviewers (PJ and MG) and agreement was reached by consensus. Where data could be aggregated they were analysed using a fixed effects model and reported as a weighted mean difference (MD) and its associated 95% confidence interval (95% CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-10-28 16:01:27 +0100" MODIFIED_BY="Emma J Welsh">
<P>Four trials were included in the review. Of these, two were randomised parallel studies, one was a crossover study and the other had a sequential design. A total of 84 patients were involved. Study quality was mixed and the studies were short (typically two weeks). All studies showed a similar direction and size of effect. In the randomised parallel studies, acetazolamide caused a metabolic acidosis and produced a non-significant fall in PCO2 (MD -0.41 kPa; 95% CI -0.91, 0.09; N=2) and a significant rise in PO2 (MD 1.54 kPa; 95% CI 0.97, 2.11; N=2). One study reported an improvement in sleep but there were no data concerning outcomes such as health status, symptoms, exacerbation rate, hospital admissions or deaths. Side effects were reported infrequently. An update search conducted in October 2005 did not identify any further studies.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Acetazolamide can produce a small increase in arterial PO2 and fall in PCO2. These conclusions are drawn from a few small short studies that were not all of high quality. It is not known whether this physiological improvement is associated with clinical benefit.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-10-28 16:25:17 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Chronic ventilatory failure leading to chronic hypercapnia occurs in a small number of patients with COPD in the end-stage of their disease. This is associated with high plasma bicarbonate. The raised bicarbonate level buffers the effect of the raised arterial carbon dioxide level (PCO2) so reducing the drive to breathe associated with the respiratory acidosis. Promotion of renal excretion of bicarbonate by inhibition of carbonic anhydrase produces a mild metabolic acidosis, which can increase lung ventilation. The mild acidosis might also cause favourable shifts in the oxygen (O2) dissociation curve. The carbonic anhydrase inhibitor acetazolamide is used in the treatment of acute mountain sickness, and in recent years, clinicians have used it as an adjunct to treatment in patients with ventilatory failure due to a variety of causes including chronic obstructive pulmonary disease (COPD). This review examines the clinical trial data for this class of agents in this setting.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine whether carbonic anhydrase inhibitors improve patients with ventilatory failure secondary COPD in terms of pulmonary gas exchange and clinical outcomes.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-10-28 16:25:17 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-07-21 16:24:28 +0100" MODIFIED_BY="Toby J Lasserson">
<CRIT_STUDIES>
<P>Any RCT or quasi-RCT, comparing blood gases in treated and untreated groups of patients with ventilatory failure due to COPD.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Adults with acute or chronic ventilatory failure (PO2 less than 8 kPa and PCO2 greater than 6.5 kPa) due to COPD. Both spontaneously breathing and ventilated patients will be included.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Any oral or intravenous carbonic anhydrase treatment. Dosing may be single or repeated. Treatment must be compared with a control group (usual care or placebo). </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-07-21 16:24:28 +0100" MODIFIED_BY="Toby J Lasserson">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-07-21 16:23:50 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Blood gas data</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-07-21 16:24:28 +0100" MODIFIED_BY="Toby J Lasserson">
<OL>
<LI>Progression to ventilation or speed of weaning if ventilation established. Mortality in hospital and length of stay in intensive care unit or hospital </LI>
<LI>Lung function </LI>
<LI>Side effects</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-10-28 16:25:17 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2010-10-28 16:25:17 +0100" MODIFIED_BY="[Empty name]">
<P>Trials were identified using the Cochrane Airways Group Specialised Register of trials, which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and CINAHL, and handsearching of respiratory journals and meeting abstracts (please see the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/AIRWAYS/frame.html">Airways Group Module</A> for further details). All records in the Specialised Register coded as 'COPD' were searched using the following terms:</P>
<P>"carbonic anhydrase*" OR "Carbonate dehydratase*" OR acetazolamide OR Diamox OR dorzolamide OR brinzolamide</P>
<P>The most recent search was conducted in October 2010.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-07-21 16:24:54 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Following this, the bibliographies of each RCT identified were searched for additional papers that may contain RCTs. The bibliographies of review articles concerning treatment of respiratory failure were also searched. Authors of identified RCTs were contacted for other published and unpublished studies. In addition, the pharmaceutical companies who manufacture carbonic anhydrase inhibitors were contacted.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-10-28 16:02:00 +0100" MODIFIED_BY="Emma J Welsh">
<P>Both reviewers assessed the full papers of all trials that appeared potentially relevant for inclusion. Agreement was achieved by consensus. Data from the trials were extracted by two reviewers and sent to the authors for verification. If author verification was not possible, the second reviewer assessed the accuracy of data extraction.</P>
<SUBSECTION>
<HEADING LEVEL="5">Statistical considerations</HEADING>
<P>The analysis compared carbonic anhydrase inhibitor versus placebo (or 'standard treatment' or 'usual care'). Continuous outcome measures were entered as mean differences (MD) or standardised mean differences (SMD) depending upon whether data were measured on the same or different metrics.</P>
<P>Categorical outcomes were analysed as odds ratios.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Pooling Data</HEADING>
<P>Data were only pooled within subgroups - defined as randomised, or non-randomised studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Assessment of Methodological Quality</HEADING>
<P>Methodological quality assessment was performed by two reviewers using the Cochrane approach and the method of Jadad.</P>
<P>Inter-rater reliability was measured using kappa, and weighted kappa statistics.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-10-28 16:18:51 +0100" MODIFIED_BY="Emma J Welsh">
<STUDY_DESCRIPTION MODIFIED="2010-10-28 16:18:30 +0100" MODIFIED_BY="Emma J Welsh">
<SEARCH_RESULTS MODIFIED="2010-10-28 16:05:02 +0100" MODIFIED_BY="Emma J Welsh">
<P>Eight references were identified by searches conducted on the Airways Group register. Of these, five were excluded (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table) and three were included. A further study (<LINK REF="STD-Wagenaar-2003" TYPE="STUDY">Wagenaar 2003</LINK>) was identified through correspondence with an author of one of the primary trials (Prof Hans Folgering). An update search was conducted in October 2003 - two references were identified: one study which had been previously included as an unpublished trial (<LINK REF="STD-Wagenaar-2003" TYPE="STUDY">Wagenaar 2003</LINK>) and one study was subsequently excluded (<LINK REF="STD-Wagenaar-2002" TYPE="STUDY">Wagenaar 2002</LINK>; inadequate control). Update searches conducted in October 2007 and October 2010 did not identify any further studies relevant to the review.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-10-28 16:18:30 +0100" MODIFIED_BY="Emma J Welsh">
<P>
<LINK REF="STD-Skatrud-1983" TYPE="STUDY">Skatrud 1983</LINK> involved 15 patients. We excluded the results of two patients who did not have clinically significant COPD. Mean age was 56 years (+/-2), mean FEV1 was 38 L (+/- 6%). Patients with FEV1 less 0.5 L were excluded from this study. The participants were allocated in a quasi-randomised fashion to receive either Acetazolamide or placebo in a single blind manner. The inclusion criteria were chronic CO2 retention. Acetazolamide was administered twice daily in 250 mg BD for 10 days.</P>
<P>The outcome measures were blood gas changes at day 10. Other reported outcomes were lung function, oxygen consumption, mouth occlusion pressure and CO2 responses. PO2 measurements were not given in the paper, but Dr Skatrud was able to provide arterial oxygen levels (PO2) on five patients.</P>
<P>The paper of <LINK REF="STD-Hacki-1983" TYPE="STUDY">Hacki 1983</LINK> reported results of 14 patients (6 exclusions, no gender breakdown) who were randomised to receive either acetazolamide 250 mg or placebo in a double blind crossover trial. Crossover occurred after 3, 6 and 9 days. The results reported in the review were taken from the longer-term follow-up period. Inclusion criteria were PO2 &lt; 60 mm Hg, CO2 &gt; 45 mm Hg and blood pH &gt; 7.38. Mean FEV1 was 0.89 L (+/- 0.29) at baseline, vital capacity was 2.26 L (+/- 0.78).</P>
<P>
<LINK REF="STD-Vos-1994" TYPE="STUDY">Vos 1994</LINK> reported the effect of acetazolamide on 53 patients (39 male) with a mean age of 65 years (+/- 9) who initially received either room air or oxygen in random order via nasal cannulae. They then received medroxyprogesterone acetate (25 mg), acetazolamide (250 mg) or placebo in random order on a daily basis given in identical capsules.</P>
<P>Inclusion criteria were listed as ATS defined COPD, with FEV1 &gt; 65% predicted value, and daytime arterial PaO2 of &gt; 8.5 kPa.</P>
<P>Patients were excluded from the study who had experienced thromboembolic events in the past, and who had factors suggesting possible obstructive sleep apnoea. Usual medication remained unchanged.</P>
<P>
<LINK REF="STD-Wagenaar-2003" TYPE="STUDY">Wagenaar 2003</LINK> involved 12 stable COPD patients (no gender ratio given) whose mean age was 68 years (+/- 2). No dropouts were reported. Acetazolamide 250 mg twice daily was administered over two weeks. Inclusion criterion was severe airflow limitation and PaCO2 &gt; 6 kPa. After baseline measurements, all patients received placebo over two weeks. The patients then received acetazolamide or medroxyprogesterone acetate.</P>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-10-28 16:15:00 +0100" MODIFIED_BY="Emma J Welsh">
<P>The <LINK REF="STD-Hacki-1983" TYPE="STUDY">Hacki 1983</LINK> paper scored three points on the Jadad scale. It was a crossover study; however, we have reported the results of five patients who continued on acetazolamide and eight patients who were followed up after the initial period of treatment. The results from this trial should therefore be treated with caution, since it is not clear whether those who continued the treatment were defined as responsive to acetazolamide.</P>
<P>
<LINK REF="STD-Skatrud-1983" TYPE="STUDY">Skatrud 1983</LINK> scored one point on the Jadad scale and was graded C on the Cochrane Collaboration scale of evidence. The study was single blind and there were problems in extracting the data we required due to the failure to report group means but selective presentation of results from ACET responders limit the data which we can use for the review.</P>
<P>
<LINK REF="STD-Vos-1994" TYPE="STUDY">Vos 1994</LINK> scored three points on the Jadad scale. The paper did not score more than three as there was no description of withdrawals and drop outs from the study. The absence of description of how the study was randomised precluded a higher score. Nevertheless the study was well described and otherwise exhaustive.</P>
<P>
<LINK REF="STD-Wagenaar-2003" TYPE="STUDY">Wagenaar 2003</LINK> was a crossover trial. The results were reported as an aggregate of the two treatment arms. The patients were randomised to receive acetazolamide and medroxyprogesterone acetate. Methodologically this study was not satisfactory, as patients were not randomised to treatment versus control.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-10-28 16:18:51 +0100" MODIFIED_BY="Emma J Welsh">
<P>Not all of the analyses could be pooled as one was a crossover study (<LINK REF="STD-Wagenaar-2003" TYPE="STUDY">Wagenaar 2003</LINK>) and another had a sequential design (<LINK REF="STD-Skatrud-1983" TYPE="STUDY">Skatrud 1983</LINK>) so pooling data from these trials with the papers from <LINK REF="STD-Vos-1994" TYPE="STUDY">Vos 1994</LINK>; <LINK REF="STD-Hacki-1983" TYPE="STUDY">Hacki 1983</LINK> was not appropriate.</P>
<P>BLOOD GAS</P>
<P>Acetazolamide led to an improvement in arterial blood gases in all four studies. Arterial pH fell, indicating that the acetazolamide was being taken by the patients and caused a mild metabolic acidosis. This was associated with an overall reduction in PCO2 and a slightly larger improvement in PO2. In the randomised studies (<LINK REF="STD-Hacki-1983" TYPE="STUDY">Hacki 1983</LINK>; <LINK REF="STD-Vos-1994" TYPE="STUDY">Vos 1994</LINK>) there was a non-significant fall in PCO2 (MD -0.41 kPa; 95% CI -0.91, 0.09; N=2) and a significant rise in PO2 (MD 1.54 kPa; 95% CI 0.97 to 2.11; N=2).</P>
<P>(NB - the PO2 readings for <LINK REF="STD-Skatrud-1983" TYPE="STUDY">Skatrud 1983</LINK> are incomplete, and correspondence with the author yielded data only for five patients from the study)</P>
<P>The administration of Acetozolomide led to an improvement in arterial blood gases in all four studies that we reviewed. Arterial pH fell and was associated with an overall reduction in PCO2 and an improvement in PO2. In the randomised studies (<LINK REF="STD-Hacki-1983" TYPE="STUDY">Hacki 1983</LINK>; <LINK REF="STD-Vos-1994" TYPE="STUDY">Vos 1994</LINK>) PO2 was significantly better for the treatment groups with an improvement ranging from 15 to 27%. The fall in CO2 was between 3 and 12% for all the studies.</P>
<P>LUNG FUNCTION</P>
<P>Lung function data were reported rarely and not in a form that permitted pooling.</P>
<P>PROGRESSION TO VENTILATION OR SPEED OF WEANING IF VENTILATION ESTABLISHED</P>
<P>No paper reported on this outcome. However, given that patients were studied in a stable condition, large numbers of patients were not to be expected.</P>
<P>LENGTH OF HOSPITAL STAY</P>
<P>None of the papers stated whether the patients had been admitted, but it is implicit that the subjects were stable outpatients.</P>
<P>SIDE EFFECTS</P>
<P>The studies suggest that the dose used (250 mg twice daily) was well tolerated. <LINK REF="STD-Hacki-1983" TYPE="STUDY">Hacki 1983</LINK> reported that no patient had suffered adverse effects. Overall, three patients had parasthesia (one in <LINK REF="STD-Skatrud-1983" TYPE="STUDY">Skatrud 1983</LINK>, and two in <LINK REF="STD-Vos-1994" TYPE="STUDY">Vos 1994</LINK>). One patient complained of vertigo and one suffered from nausea in <LINK REF="STD-Vos-1994" TYPE="STUDY">Vos 1994</LINK>. No side-effect data were available from <LINK REF="STD-Wagenaar-2003" TYPE="STUDY">Wagenaar 2003</LINK> but no dropouts were reported due to drug side effects.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-10-28 15:59:54 +0100" MODIFIED_BY="Emma J Welsh">
<P>Acetazolamide produced a small fall in arterial PO2 and rise in arterial PO2 in all four studies. The study populations were all small and the treatment duration was short. Only that of <LINK REF="STD-Hacki-1983" TYPE="STUDY">Hacki 1983</LINK> looked beyond an acute effect, although in that study, the criteria for inclusion in the longer-term treatment period were not stated explicitly. None of the studies looked at symptoms other than side effects, although one reported an improvement in the quality of sleep (<LINK REF="STD-Vos-1994" TYPE="STUDY">Vos 1994</LINK>). The same study reported an improvement in hypercapnic and hypoxaemic ventilatory responses, but this was not associated with any reported increase in well being. There were approximately equal numbers of patients reporting a favourable judgement as to the treatment effect (7 out of 16 receiving acetazolamide versus 8 out of 18 receiving placebo).</P>
<P>None of the studies were dose ranging, in that all trials used 250 mg twice daily and it is not clear whether greater effects might be obtained with higher doses. Nevertheless the dose used was sufficient to cause a significant change in blood pH. From the available data, the drug appeared to be well tolerated in this dose. One striking finding is the absence of even medium term data in the studies with only five patients having received the drug for more than two weeks (<LINK REF="STD-Hacki-1983" TYPE="STUDY">Hacki 1983</LINK>). It is possible that side effects would be more likely with longer-term administration.</P>
<P>Ventilatory failure usually occurs late in the natural history of COPD. It is not unusual for patients with an acute exacerbation to require admission to hospital with acute respiratory acidosis. These patients are managed with increased doses of bronchodilators, corticosteroids and non-invasive ventilation. Usually the hypercapnia resolves with treatment. Patients who are chronically hypercapnic usually have more severe disease and a worse prognosis. They also require long term oxygen therapy (LTOT) at home for &gt; 15 hours per day. One intriguing possibility is that long term treatment with acetazolamide might improve the arterial PO2 sufficiently to delay the point at which patients may need LTOT, or improve the PO2 above the level at which LTOT is required (7.5 kPa when breathing room air in a clinically stable state). It seems likely; however, those patients with the worst FEV1 are those least likely to respond. Indeed <LINK REF="STD-Skatrud-1983" TYPE="STUDY">Skatrud 1983</LINK> noted that patients with the worst spirometry were the least likely to respond. The patient groups in these studies were relatively mild in terms of hypercapnia and clinicians will want to know whether the drug is equally effective in patients with more severe hypercapnia, many of whom may be very symptomatic and in whom chronic ventilatory support might be considered.</P>
<P>In conclusion, whilst the studies were small, short and often of poor design, it does appear that acetazolamide reduces arterial PCO2 and increases arterial PO2 over the short term with few reported side-effects. There is no evidence as to whether this physiological improvement translates into improved symptoms (with the sole exception of a single report of improved sleep by <LINK REF="STD-Vos-1994" TYPE="STUDY">Vos 1994</LINK>), a reduction in exacerbations, hospital admissions or mortality or an improvement in health status (health-related quality of life).</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-10-28 16:17:12 +0100" MODIFIED_BY="Emma J Welsh">
<IMPLICATIONS_PRACTICE>
<P>Short-term clinical trial data suggest that acetazolamide has a small beneficial effect on arterial PCO2 and PO2. There is no evidence of other clinical benefits. The drug appears to be well tolerated, with few side-effects over two weeks in a dose of 250 mg twice daily, so may be considered in patients with chronic hypercapnic ventilatory failure.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-10-28 16:17:12 +0100" MODIFIED_BY="Emma J Welsh">
<P>Well-controlled randomised longer-term studies are required. Such studies should measure symptoms, sleep, health status, need for LTOT, exacerbation frequency, hospitals admissions and deaths. They would need to be multi-centred and have adequate power to detect a difference between the two treatments and sufficiently resourced to accommodate the lengthy follow-up period (between three and five years).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors of this review would like to thank the following people: Jane Dennis, Stephen Milan, Anna Bara and Karen Blackhall (members of the Cochrane Airways Group) for their continued support. A note of thanks should also be made for the Cupertino of Prof. Hans Folgering and Dr James Skatrud who very kindly supplied us with unpublished data. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>There are no known conflicts of interest. There are no external sources of support. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Paul Jones - conceived the protocol, assessed search results, entered data and interpreted the results. </P>
<P>Mike Greenstone - assisted with protocol conception, assessment of search results, and overall interpretation.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-08-21 16:47:20 +0100" MODIFIED_BY="Emma Dennett">
<STUDIES MODIFIED="2017-08-21 16:42:49 +0100" MODIFIED_BY="Emma J Dennett">
<INCLUDED_STUDIES MODIFIED="2010-10-28 16:28:08 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Hacki-1983" NAME="Hacki 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hacki M, Waldbeck G, Brandli O</AU>
<TI>Acetazolomide in hypercapnic chronic obstructive lung disease - a renaissance?</TI>
<TO>Acetazolomide bei hyperkapnischer chronischer obstruktiver Lungenkrankheit - eine Renaissance?</TO>
<SO>Schweizerishce medizinische Wochenschift</SO>
<YR>1983</YR>
<VL>113</VL>
<NO>3</NO>
<PG>110-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3026654"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3026653"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Skatrud-1983" NAME="Skatrud 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skatrud J, Dempsey J</AU>
<TI>Relative effectiveness of Acetazlomide versus medroxyprogesterone acetate in correction of chronic carbon dioxide retention</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1983</YR>
<VL>127</VL>
<NO>4</NO>
<PG>405-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3026656"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3026655"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vos-1994" NAME="Vos 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vos P, Folgering H, de Boo T, Lemmens W, van Herwaarden C</AU>
<TI>Effects of chloromadione acetate and oxygen on awake and asleep gas exchange in patients with chronic obstructive pulmonary disease</TI>
<SO>European Respiratory Journal</SO>
<YR>1994</YR>
<VL>7</VL>
<NO>5</NO>
<PG>850-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3026658"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3026657"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Wagenaar-2003" MODIFIED="2010-10-28 16:28:08 +0100" MODIFIED_BY="[Empty name]" NAME="Wagenaar 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wagenaar M, Vos P, Heijdra Y, Teppema L, Folgering H</AU>
<TI>Comparison of acetazolamide and medroxyprogesterone as respiratory stimulants in hypercapnic patients with COPD</TI>
<SO>Chest</SO>
<YR>2003</YR>
<VL>123</VL>
<NO>5</NO>
<PG>1450-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3026660"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-10-28 16:28:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Wagenaar M, Vos P, Heijdra Y, van Herwaarden C, Folgering H</AU>
<TI>The effects of Medroxyprogesterone acetate and acetazolomide on the nocturnal oxygen saturation in COPD patients</TI>
<SO>[unpublished]</SO>
<YR>1999</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3026661"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3026659"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Chin-1983" NAME="Chin 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chin R, Pesce R</AU>
<TI>Practical aspects in management of respiratory failure in chronic obstructive pulmonary disease</TI>
<SO>Critical Care Quarterly</SO>
<YR>1983</YR>
<VL>6</VL>
<NO>2</NO>
<PG>1-21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3026663"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3026662"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DeBacker-1995" NAME="DeBacker 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DeBacker W, Verbraecken J, Willemen M, Wittsaele W, DeCock W, van de Hayning P</AU>
<TI>Central apnea index decreases after prolonged treatment with acetazolomide</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1995</YR>
<VL>151</VL>
<NO>1</NO>
<PG>87-91</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3026665"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3026664"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Izquierido-1994" NAME="Izquierido 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Izquierdo J. Morera J. [Respiratory stimulants and COPD]. [Spanish] [Editorial] Revista Clinica Espanola. 194(12):1003-5, 1994 Dec. &lt;br&gt;UI: 7863044 &lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Izquierido J, Morera J</AU>
<TI>Respiratory stimulants and COPD</TI>
<TO>Estimulantes respiratorios y EPOC</TO>
<SO>Revista Clinica Espanola</SO>
<YR>1994</YR>
<VL>194</VL>
<NO>12</NO>
<PG>1003-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3026667"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3026666"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noone-1994" NAME="Noone 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Noone P, Olivier K, Knowles M</AU>
<TI>Modulation of the ionic milieu of the airway in health and disease</TI>
<SO>Annual Review of Medicine</SO>
<YR>1994</YR>
<VL>45</VL>
<PG>421-34</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3026669"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3026668"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vos-1995" NAME="Vos 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vos P, Folgering H, van Herwaarden C</AU>
<TI>Visual attention in patients with chronic obstructive pulmonary disease</TI>
<SO>Biological Psychology</SO>
<YR>1995</YR>
<VL>41</VL>
<NO>3</NO>
<PG>295-305</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3026671"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3026670"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wagenaar-2002" NAME="Wagenaar 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wagenaar M, Vos PJ, Heijdra YF, Teppema LJ, Folgering HT</AU>
<TI>Combined treatment with acetazolamide and medroxyprogesterone in chronic obstructive pulmonary disease patients</TI>
<SO>European Respiratory Journal</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>5</NO>
<PG>1130-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3026673"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3026672"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2017-08-21 16:42:49 +0100" MODIFIED_BY="Emma J Dennett">
<STUDY DATA_SOURCE="PUB" ID="STD-Faisy-2016" MODIFIED="2017-08-21 16:42:49 +0100" MODIFIED_BY="Emma J Dennett" NAME="Faisy 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-08-21 16:42:49 +0100" MODIFIED_BY="Emma J Dennett" NOTES="&lt;p&gt;In-Process&lt;/p&gt;" NOTES_MODIFIED="2017-08-21 16:42:49 +0100" NOTES_MODIFIED_BY="Emma J Dennett" PRIMARY="NO" TYPE="OTHER">
<AU>Faisy C, Meziani F, Planquette B, Clavel M, Gacouin A, Bornstain C, et al</AU>
<TI>Effect of acetazolamide vs placebo on duration of invasive mechanical ventilation among patients with chronic obstructive pulmonary disease: a randomized clinical trial</TI>
<SO>JAMA</SO>
<YR>2016</YR>
<VL>315</VL>
<NO>5</NO>
<PG>480-8</PG>
<PB>American Medical Association (E-mail: smcleod@itsa.ucsf.edu)</PB>
<CY>United States</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6614831"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6614830"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fontana-2016" MODIFIED="2017-08-21 16:42:49 +0100" MODIFIED_BY="Emma J Dennett" NAME="Fontana 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-08-21 16:42:49 +0100" MODIFIED_BY="Emma J Dennett" NOTES="&lt;p&gt;MEDLINE&lt;/p&gt;" NOTES_MODIFIED="2017-08-21 16:42:49 +0100" NOTES_MODIFIED_BY="Emma J Dennett" PRIMARY="NO" TYPE="OTHER">
<AU>Fontana V, Santinelli S, Internullo M, Marinelli P, Sardo L, Alessandrini G, et al</AU>
<TI>Effect of acetazolamide on post-niv metabolic alkalosis in acute exacerbated COPD patients</TI>
<SO>European review for medical and pharmacological sciences</SO>
<YR>2016</YR>
<VL>20</VL>
<NO>1</NO>
<PG>37-43</PG>
<CY>Italy</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6614833"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6614832"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rialp-2017" MODIFIED="2017-08-21 16:42:49 +0100" MODIFIED_BY="Emma J Dennett" NAME="Rialp 2017" YEAR="2017">
<REFERENCE MODIFIED="2017-08-21 16:42:49 +0100" MODIFIED_BY="Emma J Dennett" PRIMARY="NO" TYPE="OTHER">
<AU>Rialp Cervera G, Raurich Puigdevall JM, Moran Chorro I, Martin Delgado MC, Heras la Calle G, Mas Serra A, et al</AU>
<TI>Effects of early administration of acetazolamide on the duration of mechanical ventilation in patients with chronic obstructive pulmonary disease or obesity-hypoventilation syndrome with metabolic alkalosis. A randomized trial</TI>
<SO>Pulmonary pharmacology &amp; therapeutics</SO>
<YR>2017</YR>
<VL>44</VL>
<PG>30-7</PG>
<PB>Academic Press</PB>
<CY>England</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6614835"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6614834"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES/>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-08-21 16:42:49 +0100" MODIFIED_BY="Emma J Dennett">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-10-28 16:17:57 +0100" MODIFIED_BY="Emma J Welsh" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-10-28 16:17:24 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Hacki-1983">
<CHAR_METHODS>
<P>RCT, single blind, parallel group study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-28 16:17:24 +0100" MODIFIED_BY="Emma J Welsh">
<P>N = 13. Inclusion criteria: Patients with COPD, pO2 &lt;60mm Hg, pCO2 &gt; 45mm Hg, pH &gt; 7.38</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Diamox and placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Blood gases, Lung function</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-28 16:17:52 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Skatrud-1983">
<CHAR_METHODS>
<P>Sequential single blind, placebo controlled crossover trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-28 16:17:52 +0100" MODIFIED_BY="Emma J Welsh">
<P>N = 13. Inclusion criteria: Patients mean age was 56 years (+/- 2). Mean weight was 90 kg (+/- 7). Patients with FEV1 &lt; 0.5 L were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Placebo was administered before both ACET and MPA</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Blood gases, Lung function, Response to exercise, mouth occlusion pressure, CO2 response.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-28 16:17:57 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Vos-1994">
<CHAR_METHODS>
<P>RCT, double blind, parallel study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-28 16:17:57 +0100" MODIFIED_BY="Emma J Welsh">
<P>N = 53. Inclusion criteria: FEV1 &lt; 65% predicted. Daytime PaO2 &lt; 8.5 kPa.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>ACET, Chlormadinone or placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Blood gases, Lung function, ventilatory responses, end tidal CO2, sleep quality, nocturnal oxygen saturations.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wagenaar-2003">
<CHAR_METHODS>
<P>Crossover double blind, placebo controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 12</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Chin-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-DeBacker-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not COPD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Izquierido-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Noone-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vos-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Healthy controls</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wagenaar-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT assessing the effects of combination therapy. Inadequate control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2017-08-21 16:42:49 +0100" MODIFIED_BY="Emma J Dennett" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Faisy-2016">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Fontana-2016">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Rialp-2017">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hacki-1983">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Skatrud-1983">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Vos-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wagenaar-2003">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-10-28 15:59:20 +0100" MODIFIED_BY="Emma J Welsh">
<COMPARISON ID="CMP-001" MODIFIED="2010-10-28 15:59:20 +0100" MODIFIED_BY="Emma J Welsh" NO="1">
<NAME>Diamox versus control</NAME>
<CONT_OUTCOME CHI2="1.7190817629228896" CI_END="-0.2461032568678574" CI_START="-0.9075036715274494" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5768034641976534" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.6326999455764989" P_Q="0.6770572838682151" P_Z="6.295657371058438E-4" Q="0.7799993630456449" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="47" TOTAL_2="51" UNITS="" WEIGHT="300.0" Z="3.4185464385207247">
<NAME>PCO2 (kPa)</NAME>
<GROUP_LABEL_1>Diamox</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.9390823998772441" CI_END="0.08982380426549935" CI_START="-0.9077154722108716" DF="1" EFFECT_SIZE="-0.40894583397268613" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" NO="1" P_CHI2="0.33251409923674824" P_Z="0.10805599649351644" STUDIES="2" TAU2="0.0" TOTAL_1="22" TOTAL_2="26" WEIGHT="100.0" Z="1.6069925768645106">
<NAME>Randomised Studies</NAME>
<CONT_DATA CI_END="0.45372952648799825" CI_START="-0.8537295264879968" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" MEAN_1="5.9" MEAN_2="6.1" ORDER="1631" SD_1="0.5" SD_2="0.7" SE="0.3335416016031583" STUDY_ID="STD-Hacki-1983" TOTAL_1="5" TOTAL_2="8" WEIGHT="58.21083320546264"/>
<CONT_DATA CI_END="0.07155724307249767" CI_START="-1.4715572430724961" EFFECT_SIZE="-0.6999999999999993" ESTIMABLE="YES" MEAN_1="5.9" MEAN_2="6.6" ORDER="1632" SD_1="1.3" SD_2="1.0" SE="0.39365888820327416" STUDY_ID="STD-Vos-1994" TOTAL_1="17" TOTAL_2="18" WEIGHT="41.78916679453736"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.1783647508723165" CI_START="-1.2216352491276838" DF="0" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" NO="2" P_CHI2="1.0" P_Z="0.008534920413884423" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="2.6301420225576284">
<NAME>Crossover studies</NAME>
<CONT_DATA CI_END="-0.1783647508723165" CI_START="-1.2216352491276838" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="5.6" MEAN_2="6.3" ORDER="1633" SD_1="0.7" SD_2="0.6" SE="0.26614532371118854" STUDY_ID="STD-Wagenaar-2003" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.10072456463985846" CI_START="-1.5607245646398575" DF="0" EFFECT_SIZE="-0.7299999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.03" NO="3" P_CHI2="1.0" P_Z="0.08501152818920692" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.00000000000001" Z="1.7223202125177537">
<NAME>Sequential studies</NAME>
<CONT_DATA CI_END="0.10072456463985846" CI_START="-1.5607245646398575" EFFECT_SIZE="-0.7299999999999995" ESTIMABLE="YES" MEAN_1="6.45" MEAN_2="7.18" ORDER="1634" SD_1="1.27" SD_2="0.85" SE="0.42384685187713006" STUDY_ID="STD-Skatrud-1983" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6917159502359659" CI_END="-0.9574452159449953" CI_START="-1.9216901075535644" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.4395676617492799" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.8751507084984544" P_Q="0.8075993463512552" P_Z="4.8496879829519335E-9" Q="0.42737867660715123" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="39" TOTAL_2="43" UNITS="" WEIGHT="300.0" Z="5.852249350536365">
<NAME>PO2 (kPa)</NAME>
<GROUP_LABEL_1>Diamox</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.2643372736288149" CI_END="-0.970394136046022" CI_START="-2.112083930871046" DF="1" EFFECT_SIZE="-1.541239033458534" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="0.6071559712065231" P_Z="1.2114619567105588E-7" STUDIES="2" TAU2="0.0" TOTAL_1="22" TOTAL_2="26" WEIGHT="100.0" Z="5.291757902783068">
<NAME>Randomised Studies</NAME>
<CONT_DATA CI_END="-0.8680420381337364" CI_START="-2.531957961866264" EFFECT_SIZE="-1.7000000000000002" ESTIMABLE="YES" MEAN_1="-7.9" MEAN_2="-6.2" ORDER="1635" SD_1="0.03" SD_2="1.2" SE="0.4244761477397758" STUDY_ID="STD-Hacki-1983" TOTAL_1="5" TOTAL_2="8" WEIGHT="47.0796778195112"/>
<CONT_DATA CI_END="-0.6152941620322456" CI_START="-2.184705837967755" EFFECT_SIZE="-1.4000000000000004" ESTIMABLE="YES" MEAN_1="-9.4" MEAN_2="-8.0" ORDER="1636" SD_1="1.4" SD_2="0.9" SE="0.40036747825848545" STUDY_ID="STD-Vos-1994" TOTAL_1="17" TOTAL_2="18" WEIGHT="52.9203221804888"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.14756443112489093" CI_START="-2.2524355688751077" DF="0" EFFECT_SIZE="-1.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="1.0" P_Z="0.02543211873242458" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="2.234775078879122">
<NAME>Crossover studies</NAME>
<CONT_DATA CI_END="-0.14756443112489093" CI_START="-2.2524355688751077" EFFECT_SIZE="-1.1999999999999993" ESTIMABLE="YES" MEAN_1="-10.0" MEAN_2="-8.8" ORDER="1637" SD_1="1.5" SD_2="1.1" SE="0.5369667897862337" STUDY_ID="STD-Wagenaar-2003" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5893396677042282" CI_START="-2.889339667704227" DF="0" EFFECT_SIZE="-1.1499999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.03" NO="3" P_CHI2="1.0" P_Z="0.19502017994661264" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="99.99999999999999" Z="1.295870280010393">
<NAME>Sequential Studies</NAME>
<CONT_DATA CI_END="0.5893396677042282" CI_START="-2.889339667704227" EFFECT_SIZE="-1.1499999999999995" ESTIMABLE="YES" MEAN_1="-7.68" MEAN_2="-6.53" ORDER="1638" SD_1="1.61" SD_2="1.16" SE="0.8874345046255527" STUDY_ID="STD-Skatrud-1983" TOTAL_1="5" TOTAL_2="5" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5097383671090134" CI_END="-0.04043257663085853" CI_START="-0.06545159166458524" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.052942084147721884" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="0.9167468441409161" P_Q="0.7750178875083508" P_Z="1.087157450651181E-16" Q="0.5097383671090133" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="47" TOTAL_2="51" UNITS="" WEIGHT="300.0" Z="8.294857176123415">
<NAME>pH</NAME>
<GROUP_LABEL_1>Diamox</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.1008662882286666E-27" CI_END="-0.031015987642693112" CI_START="-0.06898401235730744" DF="1" EFFECT_SIZE="-0.05000000000000028" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" NO="1" P_CHI2="0.9999999999999635" P_Z="2.441377964990612E-7" STUDIES="2" TAU2="0.0" TOTAL_1="22" TOTAL_2="26" WEIGHT="100.0" Z="5.162143670291207">
<NAME>Randomised Studies</NAME>
<CONT_DATA CI_END="-0.022806603320224432" CI_START="-0.0771933966797752" EFFECT_SIZE="-0.04999999999999982" ESTIMABLE="YES" MEAN_1="7.32" MEAN_2="7.37" ORDER="1639" SD_1="0.03" SD_2="0.01" SE="0.013874436925511607" STUDY_ID="STD-Hacki-1983" TOTAL_1="5" TOTAL_2="8" WEIGHT="48.735912275357904"/>
<CONT_DATA CI_END="-0.023485625186307355" CI_START="-0.07651437481369407" EFFECT_SIZE="-0.05000000000000071" ESTIMABLE="YES" MEAN_1="7.35" MEAN_2="7.4" ORDER="1640" SD_1="0.04" SD_2="0.04" SE="0.013527990831890463" STUDY_ID="STD-Vos-1994" TOTAL_1="17" TOTAL_2="18" WEIGHT="51.264087724642096"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.02599544161822416" CI_START="-0.07400455838177726" DF="0" EFFECT_SIZE="-0.05000000000000071" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" NO="2" P_CHI2="1.0" P_Z="4.4557090604369236E-5" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="4.082482904638689">
<NAME>Crossover studies</NAME>
<CONT_DATA CI_END="-0.02599544161822416" CI_START="-0.07400455838177726" EFFECT_SIZE="-0.05000000000000071" ESTIMABLE="YES" MEAN_1="7.35" MEAN_2="7.4" ORDER="1641" SD_1="0.03" SD_2="0.03" SE="0.01224744871391589" STUDY_ID="STD-Wagenaar-2003" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.036937166300518645" CI_START="-0.08306283369948235" DF="0" EFFECT_SIZE="-0.0600000000000005" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.03" NO="3" P_CHI2="1.0" P_Z="3.41417357715733E-7" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0" Z="5.099019513592827">
<NAME>Sequential Studies</NAME>
<CONT_DATA CI_END="-0.036937166300518645" CI_START="-0.08306283369948235" EFFECT_SIZE="-0.0600000000000005" ESTIMABLE="YES" MEAN_1="7.34" MEAN_2="7.4" ORDER="1642" SD_1="0.03" SD_2="0.03" SE="0.011766968108291042" STUDY_ID="STD-Skatrud-1983" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.1576641441420685" CI_END="-1.3362943886651013" CI_START="-2.328020423892089" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.8321574062785952" ESTIMABLE="YES" I2="41.834134287178884" I2_Q="10.684854099120244" ID="CMP-001.04" MODIFIED="2010-10-28 15:59:20 +0100" MODIFIED_BY="Emma J Welsh" NO="4" P_CHI2="0.1606098609284754" P_Q="0.3264005461251732" P_Z="4.4262539346638213E-13" Q="2.239261862953862" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="47" TOTAL_2="51" UNITS="" WEIGHT="300.0" Z="7.241843821297807">
<NAME>HCO3</NAME>
<GROUP_LABEL_1>Diamox</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.918402281188206" CI_END="-0.9129940992064682" CI_START="-2.2859143068274146" DF="1" EFFECT_SIZE="-1.5994542030169414" ESTIMABLE="YES" I2="65.73467590654235" ID="CMP-001.04.01" NO="1" P_CHI2="0.08757468473324836" P_Z="4.954097281354491E-6" STUDIES="2" TAU2="0.0" TOTAL_1="22" TOTAL_2="26" WEIGHT="100.0" Z="4.566722254407866">
<NAME>Random studies</NAME>
<CONT_DATA CI_END="-1.250258622277499" CI_START="-4.833693010858779" EFFECT_SIZE="-3.041975816568139" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="2.0" ORDER="1643" SD_1="1.5" SD_2="1.3" SE="0.9141582235303694" STUDY_ID="STD-Hacki-1983" TOTAL_1="5" TOTAL_2="8" WEIGHT="14.678838099700963"/>
<CONT_DATA CI_END="-0.6081117868472394" CI_START="-2.094447513079048" EFFECT_SIZE="-1.3512796499631436" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="5.1" ORDER="1644" SD_1="4.8" SD_2="2.4" SE="0.3791742445156735" STUDY_ID="STD-Vos-1994" TOTAL_1="17" TOTAL_2="18" WEIGHT="85.32116190029903"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.4660734998714802" CI_START="-3.735867478173428" DF="0" EFFECT_SIZE="-2.600970489022454" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" NO="2" P_CHI2="1.0" P_Z="7.060088264733442E-6" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="4.491868893889002">
<NAME>Crossover studies</NAME>
<CONT_DATA CI_END="-1.4660734998714802" CI_START="-3.735867478173428" EFFECT_SIZE="-2.600970489022454" ESTIMABLE="YES" MEAN_1="22.8" MEAN_2="27.8" ORDER="1645" SD_1="2.0" SD_2="1.7" SE="0.5790397160880997" STUDY_ID="STD-Wagenaar-2003" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.8188448432968958" CI_START="-2.6690301612752103" DF="0" EFFECT_SIZE="-1.743937502286053" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.03" NO="3" P_CHI2="1.0" P_Z="2.200390211743149E-4" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0" Z="3.694824148214827">
<NAME>Sequential studies</NAME>
<CONT_DATA CI_END="-0.8188448432968959" CI_START="-2.6690301612752103" EFFECT_SIZE="-1.743937502286053" ESTIMABLE="YES" MEAN_1="26.08" MEAN_2="32.38" ORDER="1646" SD_1="3.65" SD_2="3.34" SE="0.4719947235184779" STUDY_ID="STD-Skatrud-1983" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>